World and Olympic heptathlon champion Jessica Ennis-Hill inspires kids to do the robot and a dad even to do the worm in a Barnsley shopping centre in Santander's 2015 Christmas commercial.

Few relationships would be immune to the pressures wrought by their ordeal: the strain of caring for their desperately sick child, their brief life as fugitives, the draining legal battles.

The West Bengal Health Department on Saturday formed teams to support surveillance and monitoring of treatment at five hospitals treating COVID-19 patients in the city. The team members will pay regular visits to these hospitals and send reports to the department, the state government said in an order. The department has also set up a dedicated help line for issues regarding the non-availability of PPEs and other supplies. The feedback and suggestions will be duly recorded and acted upon by the state government for appropriate remedial measures, the order said. The West Bengal government has also constituted a team for guidance on containment activities in different districts of the state.

The camaraderie that players share during the Indian Premier League (IPL) is what makes the tournament special for India and Royal Challengers Bangalore (RCB) captain Virat Kohli. He would have been leading RCB in the 2020 edition of the T20 league at this time, had it not been for the coronavirus pandemic forcing the postponement of the IPL until further notice.

The two interacted with resident doctors of the hospital seeking their inputs about treatment of COVID-19 patients and provided expert guidance.

The state health department has also set up a dedicated helpline for issues regarding the non-availability of PPEs and other supplies.

కరోనా మహమ్మారి నేపథ్యంలో బ్యాంకులకు, ఏటీఎం సెంటర్స్‌కు కస్టమర్ల రాకను తగ్గించేందుకు ఇండియన్ బ్యాంక్స్ అసోసియేషన్ (IBA) క్యాష్ ఉపసంహరణ విషయమై కొత్త రూల్స్ తీసుకు వచ్చింది. వీటి ద్వారా ఎలక్ట్రానిక్ ట్రాన్సాక్షన్స్ పెరగడంతో పాటు బ్యాంకులకు, ఏటీఎం సెంటర్స్‌కు ఎక్కువ మంది రావడం తగ్గుతుంది. బ్రాంచీల వద్ద క్రౌడ్‌ను నిరోధించేందుకు నగదు ఉపసంహరణ కోసం నిర్దిష్ట

Chagas diseases (CD) is a silent yet life-threatening disease caused by a protozoan parasite named Trypanosoma cruzi (T.cruzi). The disease is also known as American trypanosomiasis as it is found mainly in rural areas of America where there is a lack

Cancer is a major disease worldwide in both developed as well as developing countries. According to a study, in the year 2008, there were around 7.6 million deaths worldwide due to cancer. [1] The WHO estimate the count to rise above

Every year, 17 April is observed as World Haemophilia Day. An international awareness day for haemophilia and other bleeding disorders, World Hemophilia Day is held on the date of the birthday of Frank Schnabel, founder of the World Federation of Hemophilia.

As of today, there are 2,407,439 COVID-19 cases with 165,073 deaths. On a hopeful note, 625,202 have recovered. The virus outbreak that began in 2019 continues to cause casualties, while health experts around the globe are extensively working on developing a

Thyroid cancer is the cancer of the thyroid gland which is found at the neck's front just below Adam's apple. The thyroid gland is a butterfly-shaped gland with two lobes, one at each side joined by a narrow tissue called the

Acclaimed actor Irrfan Khan passed away on the morning of April 29 after a battle with colon infection. In 2018, he had announced that he had been diagnosed with a neuroendocrine tumour and he had undergone treatment in the UK for a

Stroke is ranked as the second leading cause of death and the third leading cause of disability worldwide, as per the World Health Organization. It is estimated that 70 per cent of stroke and 87 per cent of deaths caused by

Athlete's foot (AF), also known as tinea pedis is a fungal infection of the foot, mostly found between the toes. It is named so as the infection is common in athletes and swimmers. The AF can spread to hands or other

Thalassemia is a group of inherited blood disorders that has a similar characteristic: defective and reduced production of haemoglobin, the iron-containing protein in red blood cells that helps in carrying oxygen throughout the body. Beta-thalassemia (BT) is one of

May 3-9 is Arson Awareness Week 2020, which focuses on the crucial role that firefighters play in the community to protect the public in emergency situations. Fire accidents can occur anywhere unexpectedly including homes, factories and health-care facilities. In the United

Archives, Room Use Only - TK144.F67 1846

A drug used for treating breast cancer, known as exemestane, is more effective than a common breast cancer prevention drug, tamoxifen, in preventing breast cancer recurrence in young women who also receive post-surgical treatment to suppress ovarian function. The combined results of the Tamoxifen and Exemestane Trial and Suppression of Ovarian Function Trial were presented at the 2014 ASCO Annual Meeting in Chicago.

Former Union minister and controversial Bharatiya Janata Party MP Anantkumar Hegde has once again stoked a row by calling the freedom struggle led by Mahatma Gandhi a "drama".However, this is not the first time a leader from the ruling party has insulted the Father of the Nation.Here are other instances when BJP leaders took a swipe at Mohandas Karamchand Gandhi.

The district administration and the Corporation has asked all banks to ensure security guards at the ATMs so that they can provide hand sanitisers to the people visiting the kiosks.

The team members will pay regular visits to these hospitals and send reports to the department, the state government said in an order.

A furnace that covers the temperature range from room temperature up to 2000 K has been designed, built and implemented on the D2AM beamline at the ESRF. The QMAX furnace is devoted to the full exploration of the reciprocal hemispace located above the sample surface. It is well suited for symmetric and asymmetric 3D reciprocal space mapping. Owing to the hemispherical design of the furnace, 3D grazing-incidence small- and wide-angle scattering and diffraction measurements are possible. Inert and reactive experiments can be performed at atmospheric pressure under controlled gas flux. It is demonstrated that the QMAX furnace allows monitoring of structural phase transitions as well as microstructural evolution at the nanoscale, such as self-organization processes, crystal growth and strain relaxation. A time-resolved in situ oxidation experiment illustrates the capability to probe the high-temperature reactivity of materials.

A scanning soft X-ray spectromicroscope was recently developed based mainly on the photon-in/photon-out measurement scheme for the investigation of local electronic structures on the surfaces and interfaces of advanced materials under conditions ranging from low vacuum to helium atmosphere. The apparatus was installed at the soft X-ray beamline (BL17SU) at SPring-8. The characteristic features of the apparatus are described in detail. The feasibility of this spectromicroscope was demonstrated using soft X-ray undulator radiation. Here, based on these results, element-specific two-dimensional mapping and micro-XAFS (X-ray absorption fine structure) measurements are reported, as well as the observation of magnetic domain structures from using a reference sample of permalloy micro-dot patterns fabricated on a silicon substrate, with modest spatial resolution (e.g. ∼500 nm). Then, the X-ray radiation dose for Nafion® near the fluorine K-edge is discussed as a typical example of material that is not radiation hardened against a focused X-ray beam, for near future experiments.

A sample-injection device has been developed at SPring-8 Angstrom Compact Free-Electron Laser (SACLA) for serial femtosecond crystallography (SFX) at atmospheric pressure. Microcrystals embedded in a highly viscous carrier are stably delivered from a capillary nozzle with the aid of a coaxial gas flow and a suction device. The cartridge-type sample reservoir is easily replaceable and facilitates sample reloading or exchange. The reservoir is positioned in a cooling jacket with a temperature-regulated water flow, which is useful to prevent drastic changes in the sample temperature during data collection. This work demonstrates that the injector successfully worked in SFX of the human A2A adenosine receptor complexed with an antagonist, ZM241385, in lipidic cubic phase and for hen egg-white lysozyme microcrystals in a grease carrier. The injection device has also been applied to many kinds of proteins, not only for static structural analyses but also for dynamics studies using pump–probe techniques.

This article presents the capability of the QMAX furnace, devoted to reciprocal space mapping through X-ray scattering at high temperature up to 2000 K.

The extrasolar planet GJ 1214b has a radius of about 2.7 times that of the Earth and is about 6.5 times as massive putting it squarely into the class of exoplanets known as super-Earths.

The post Super-earth has an atmosphere, but is it steamy or gassy? appeared first on Smithsonian Insider.

Observations by the NASA/ESA Hubble Space Telescope have come up with a new class of planet, a waterworld enshrouded by a thick, steamy atmosphere. It’s smaller than Uranus but larger than Earth.

The post Waterworld enshrouded by a thick, steamy atmosphere is new class of planet appeared first on Smithsonian Insider.

The Sun’s Active Region 1429 has been shooting off flares and coronal mass ejections since it rotated into Earth’s view on March 2, 2012. Two X-class flares have been released overnight, an X1.3 and an X5.4.

The post X-Class flares released by the Sun, March 6, captured by Atmospheric Imaging Assembly appeared first on Smithsonian Insider.

 The distant planet GJ 1132b intrigued astronomers when it was discovered last year. Located just 39 light-years from Earth, it might have an atmosphere despite […]

The post Venus-like Exoplanet Might Have Oxygen Atmosphere, But Not Life appeared first on Smithsonian Insider.

On June 7 the Sun unleashed an spectacular solar flare with a substantial coronal mass ejection. A large cloud of plasma mushroomed up, and while some parts fell back into the Sun, most rushed off into space. The first two segments of this video are seen through the Atmospheric Imaging Assembly aboard NASA's Solar Dynamics Observatory. The AIA was developed by Smithsonian scientists.

The post Spectacular June 7 solar flare seen through the Atmospheric Imaging Assembly aboard Solar Dynamics Observatory appeared first on Smithsonian Insider.

Using an innovative new camera on board a sounding rocket, an international team of scientists have captured the sharpest images yet of the Sun’s outer […]

The post Camera captures sun’s atmospheric sparkles appeared first on Smithsonian Insider.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome -- commonly referred to as ME/CFS -- is a legitimate, serious, and complex systemic disease that frequently and dramatically limits the activities of affected individuals, says a new report from the Institute of Medicine.

Increasing energy demands and expanding industrial and agricultural activities worldwide are changing the composition of the atmosphere and contributing to major global challenges like climate change and air pollution. The study of atmospheric chemistry plays a key role in understanding and responding to these challenges, and research in this field has been successful in guiding policies to improve air quality in urban areas and reduce acid rain and stratospheric ozone depletion.

The end of a roadside guardrail must be designed so that it is not a hazard to occupants of a vehicle striking it and so that it absorbs energy in a crash and redirects the vehicle into a safe trajectory.

Researchers are scrambling to find effective treatments for COVID-19, which has infected more than 1 million people around the word.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Remdesivir, an experimental antiviral drug made by Gilead Sciences, has been authorized by the Food and Drug Administration for emergency use in treating severely ill COVID-19 patients.; Credit: Ulrich Perry/POOL/AFP via Getty Images

Now that the Food and Drug Administration has authorized remdesivir for emergency use in seriously ill COVID-19 patients, the experimental drug is another step closer to full approval. That's when most drugs get price tags.

Gilead Sciences, which makes remdesivir, is donating its initial supply of 1.5 million doses, but the company has signaled it will need to start charging for the drug to make production sustainable. It's unclear when that decision might be made.

"Going forward, we will develop an approach that is guided by the principles of affordability and access," Gilead CEO Daniel O'Day told shareholders during the company's annual meeting Wednesday.

In a quarterly financial filing made the same day, Gilead said its investment in remdesivir this year "could be up to $1 billion or more," much of it for scaling up manufacturing capacity.

The company also acknowledged that it's in the spotlight. "[G]iven that COVID-19 has been designated as a pandemic and represents an urgent public health crisis, we are likely to face significant public attention and scrutiny about any future business models and pricing decisions with respect to remdesivir," Gilead said in the quarterly filing.

How will the company balance its business calculations with the drug's potential value to society?

"Gilead has not yet set a price for remdesivir," company spokeswoman Sonia Choi wrote in an email to NPR. "At this time, we are focused on ensuring access to remdesivir through our donation. Post-donation, we are committed to making remdesivir both accessible and affordable to governments and patients around the world."

Among potential treatments for COVID-19, remdesivir, an intravenous drug that was once studied for Ebola, is one of the furthest along.

"It's hard to imagine a situation in which there will be more public scrutiny," said Michael Carrier, a professor at Rutgers School of Law who specializes in antitrust and pharmaceuticals. "On the one hand, Gilead will try to recover its R&D in an atmosphere in which it is able to potentially make a lot of money. On the other hand, the pressure will be intense not to charge what's viewed as too high a price."

Breaking with its usual practices, the Institute for Clinical and Economic Review, or ICER, an influential nonprofit that analyzes drug pricing, issued an expedited report on remdesivir.

"Under normal circumstances, we would be unlikely to do a report when the evidence is this raw and immature," ICER President Steven Pearson said in an interview with NPR. "But it was quite clear that the world is moving at a much quicker pace."

If the price is based just on the cost of making the drug, then a 10-day course of remdesivir should cost about $10, according to the ICER report. (Gilead said results of a recently completed study suggest a five-day course of treatment may be just as effective.)

But if the drug is priced based on the drug's effectiveness, ICER estimates it should cost around $4,500 — assuming the drug is proven to have some benefit on mortality. If it doesn't and the drug only shortens hospital stays, that value-based price goes down to $390.

Results from a federally funded study described by Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, suggested that remdesvir could reduce recovery time by a median of four days — 11 days to recovery for patients treated with remdesivir compared with 15 days for those who got a placebo. A potential survival benefit is less clear.

Rutgers's Carrier said he expects Gilead to set the remdesivir price somewhere between the $10 and $4,500 that ICER estimated. The company has already shown that it can respond to public pressure when it asked the FDA to rescind the orphan drug status it won for remdesivir, he pointed out.

"When you see that $10 figure, that sets a benchmark for a figure that is eminently affordable," Carrier said. Ultimately, he said a price more than $1,000 per treatment course would be unpopular.

Gilead "will be watched very carefully," he said, because of its prior history of pricing. He referred to two other Gilead drugs that drew scrutiny over high price tags. The company charged $1,000 per pill for Sovaldi, a cure for hepatitis C. And its HIV drug Truvada can cost $22,000 per year.

But there is such a thing as pricing remdesivir too low, said Craig Garthwaite, who directs the health care program at Northwestern University's Kellogg School of Management.

"We don't think this is the only drug we need," he said, adding that remdesivir doesn't appear to be a "home run" against the coronavirus, based on existing data. "The thing that would worry me the most is that we're somehow telling people that if you take the risky bet to try, and you'll go after a coronavirus cure and you do it, you're not going to get paid."

Instead, he said he would like to see acceptance of a generous price for remdesivir to send the message to drug companies that the best thing they can do is "dedicate every waking moment to trying to develop that cure, and that if they do that, we will pay them the value they create," he said.

During a Gilead earnings call on April 30, analysts asked executives whether they could expect similar financial returns on remdesivir as they've seen with Gilead's other drugs.

"There is no rulebook out there, other than that we need to be very thoughtful about how we can make sure we provide access of our medicines to patients around the globe," Gilead CEO O'Day said. "And do that in a sustainable way for the company, for ... shareholders, and we acknowledge that."

On May 1, the FDA authorized remdesivir for emergency use, meaning it will be easier to administer to hospitalized patients with severe disease during the pandemic, but the drug is not yet officially approved. The federal government is coordinating distribution of the treatment.

Day acknowledged on the recent earnings call that the company "could" charge for remdesivir under an emergency use authorization, but he stressed that Gilead is donating its current supply, which should last through "early summer."

To date, the National Institutes of Health said it has obligated $23 million toward its COVID-19 remdesivir trial. And the U.S. Army Medical Research Institute of Infectious Diseases did some of the early in vitro and animal studies with the medicine prior to the pandemic.

"Taxpayers are often the angel investors in pharmaceutical research and development, yet this is not reflected in the prices they pay," Reps. Lloyd Doggett, D-Texas, and Rosa DeLauro, D-Conn., wrote in a April 30 letter to Health and Human Services Secretary Alex Azar.

Concerned about remdesivir's price, they asked for a full breakdown of taxpayer funds that have gone toward the development of the medicine. "An unaffordable drug is completely ineffective," they wrote in the letter. "The substantial taxpayer investments in COVID-19 pharmaceutical research must be recognized."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Levels of air pollution significantly increase on the island of Svalbard in the Norwegian Arctic when tourist cruise ships are present, according to a recent study. With shipping levels rising in the region, the researchers recommend that stricter emissions regulations are introduced in order to limit the impact of pollution on the Arctic environment.

A recent study compared the decentralised treatment of pharmaceutical contaminants in wastewater at hospitals with centralised treatment at conventional and upgraded wastewater plants. The results suggest that additional (post) treatments may not always provide significant benefits.

A new study suggests gaps exist in the treatment of depression with many individuals who screen positive for the mental health disorder not receiving treatment, according to an article published online by JAMA Internal Medicine.

read more